HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide
Key claim: A double-blind RCT will test whether daily calcium-HMB plus vitamin D3 preserves appendicular lean mass, physical function, and resting metabolism over ~6 months in adults aged 65–85 with type 2 diabetes newly starting semaglutide.
Abstract
This randomized, double-blind, placebo-controlled trial will evaluate whether daily calcium beta-hydroxy-beta-methylbutyrate (calcium-HMB) plus vitamin D3 preserves muscle mass, physical function, and resting metabolism in adults aged 65 to 85 years with type 2 diabetes who are newly starting semaglutide as part of usual clinical care. Participants will receive calcium-HMB plus vitamin D3 or matching placebo for approximately 6 months. The primary outcome is change in appendicular lean mass measured by dual-energy X-ray absorptiometry from baseline to month 6. Secondary assessments include body composition, muscle strength, physical performance, gait, physical activity, resting metabolic rate, metabolic measures, and whole-body quantitative computed tomography. An optional mechanistic substudy of up to 36 participants will include D3-creatine dilution, nonradioactive stable isotope infusions, repeated blood sampling, a standardized meal, breath sampling, and vastus lateralis muscle biopsies at baseline and month 6.
Why this matters
Muscle loss on GLP-1 agonists is the highest-profile safety gap in the AOM-as-longevity narrative, and until now mitigation has rested on expert-opinion protein-plus-resistance-training advice rather than dedicated trials. A registered RCT of HMB plus vitamin D3 in the exact at-risk population — older adults with T2D newly starting semaglutide — moves this concern from podcast-tier discussion toward testable adjunct pharmacology, though results are pending and the intervention itself remains unproven in this context.